Critical appraisal of lurasidone in the management of schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 155-168

  Caccia, Silvio ^a   Pasina, Luca ^a   Nobili, Alessandro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Efficacy; Lurasidone; Pharmacokinetics; Pharmacology; Safety

Indexed keywords

1 (1,2 BENZISOTHIAZOL 3 YL) PIPERAZINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; CYTOCHROME P450 3A4; DIAZEPAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; ENZYME INHIBITOR; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FLUNITRAZEPAM; HALOPERIDOL; ID 11614; ID 1164; ID 14283; ID 14326; ID 20219; ID 20220; ISOTHIAZOLE DERIVATIVE; KETOCONAZOLE; LURASIDONE; MIDAZOLAM; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PEROSPIRONE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

AGITATION; AKATHISIA; ANXIETY; AREA UNDER THE CURVE; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYNDROME; FOOD; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; NAUSEA; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; QT INTERVAL; QT PROLONGATION; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT GAIN;

EID: 84860849895     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S18059     Document Type: Review

References (63)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
2. Stahl SM. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry. 2004;65(1):8-9.
3. Seeman MV. Symptoms of schizophrenia: normal adaptations to inability. Med Hypotheses. 2007;69(2):253-257.
4. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122-1129.
5. Salize HJ, McCabe R, Bullenkamp J, et al. Cost of treatment of schizophrenia in six European countries. Schizophr Res. 2009;111(1-3):70-77.
6. Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399-409.
7. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261(5562):717-719.
8. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Schizophrenia. 2nd ed. Arlington, VA: American Psychiatric Association; 2004.
9. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia:mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269-2292.
10. Gaebel W, Falkai P, Weinmann S, Wobrock T. Treatment Guidelines for Schizophrenia [Behandlungsleitlinie Schizophrenie]. Stuttgart, Germany: Steinkopf; 2006. German.
11. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments For schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1): 79-104.
12. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25(3):390-392.
13. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21(Suppl 2):106S-115S.
14. Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother. 2006;7(13):1739-1748.
15. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911-936.
16. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-526.
17. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol. 2005;19(Suppl 6):16-27.
18. Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin Drug Metab Toxicol. 2007;3(1):9-19.
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
20. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of secondvs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
21. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
22. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23(8):649-659.
23. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry. 2010;55(3):117-125.
24. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(12):1762-1784.
25. Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther. 2010;4:33-48.
26. United States Food and Drug Administration. FDA Approves Latuda to Treat Schizophrenia in Adults. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm. Accessed March 20, 2012.
27. Meyer JM, Loebel Ad, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11):1715-1726.
28. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210.
29. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4(4):251-257.
30. Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol. 2011;7(7):829-846.
31. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000;38(5):393-414.
32. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-181.
33. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011;338(2):605-614.
34. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1): 59-67.
35. Meneses A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav Brain Res. 2004;155(2):275-282.
36. Guscott M, Bristow LJ, Hadingham K, et al. Genetic knockout and Pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology. 2005;48(4): 492-502.
37. Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res. 2008;195(1):30-38.
38. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). 2011;216(4):451-473.
39. Ohno Y. Therapeutic role of 5-HT1 A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther. 2011;17(1):58-65.
40. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-1736.
41. Food and Drug Administration. Drug Approval Package. Latuda (lurasidone hydrochloride) Tablets. Sunovion Pharmaceuticals, Inc. Clinical Review; Pharmacology Review(s); Clinical Pharmacology Biopharmaceutics Review(s). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000PharmR.pdf.Accessed March 21, 2012.
42. Sunovion Pharmaceutical Inc. Latuda (lurasidone HCl) [ Prescribing Information]. Sunovion Pharmaceutical Inc. Available from: http://www.latuda.com/LatudaPrescribingInformation.pdf. Accessed March 21, 2012.
43. Potkin, SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2-3):101-107.
44. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-836.
45. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo and olanzapinecontrolled study. Am J Psychiatry. 2011;168(9):957-967.
46. Meltzer H, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled PEARL 2 trial [abstract]. Presented at: American College of Neuropsychopharmacology; December 6-10, 2009; Hollywood, Fla. Abstract 76.
47. Cucchiaro J, Potkin S, Ogasa M, Loebel A. A double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Bull. 2009;35 Suppl 1:342-343.
48. Harvey PD, Murasaki M, Cucchiaro J, Ogasa M, Loebel A. A three arm dose finding study of lurasidone: Efficacy and tolerability data. Schizophr Res. 2010;117:374-375-Abstract.
49. Loebel A, Cucchiaro J, Silva R, Ogasa M, Severs J, Marder SR. Efficacy of lurasidone in schizophrenia: Results of a pooled analysis based on a 5-factor model of schizophrenia. Schizophr Res. 2010;117:267-Abstract.
50. ® (lurasidone HCl). Available from: http://www.ds-pharma.com/news/2011/20110125.html. Accessed March 21, 2012.
51. Ogasa M, Loebel A, Cucchiaro J, et al. Effect of lurasidone on depressive symptoms in patients with schizophrenia. Schizophr Bull. 2009;35: 344-345-Abstract.
52. Cucchiaro J, Pikalov A, Ogasa M. Safety of lurasidone: Pooled analysis of five placebo-controlled trials in patients with schizophrenia. Int J Neuropsychopharmacol. 2010;13 Suppl 1:217-Abstract.
53. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7: 239-250.
54. Latuda Significantly Improves Symptoms of Schizophrenia in Fifth Positive Placebo-Controlled Study. Available from: http://www.ds-pharma.com/news/pdf/ene20101209.pdf. Accessed March 21, 2012.
55. Ehret MJ, Sopko MA. Focus on lurasidone: a new atypical antipsychotic for the treatment of schizophrenia. Formulary 2010;45:313-317.
56. United States Food and Drug Administration. Information for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). FDA alert. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm. Accessed March 21, 2012.
57. United States Food and Drug Administration. Safety Information and Adverse Event Reporting Program. Geodon (ziprasidone HCl) Dear Healthcare Professional Letter. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm170899.htm. Accessed March 21, 2012.
58. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47(3):264-268.
59. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68 Suppl 1:20-27.
60. Buchholz S, Morrow AF, Coleman PL. Atypical antipsychoticinduced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J. 2008;38(7):602-606.
61. Chwieduk CM, Scott LJ. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs. 2011;25(3):251-267.
62. Murdoch D, Keating GM. Sertindole: a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-255.
63. Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drug. 2002;62(8):1217-1251.